Status:
TERMINATED
WR 279,396 Open Label Treatment Protocol in Tunisia
Lead Sponsor:
U.S. Army Medical Research and Development Command
Collaborating Sponsors:
Walter Reed Army Institute of Research (WRAIR)
Conditions:
Cutaneous Leishmaniasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The U.S. Army has recently completed a Phase 3 clinical trial in Tunisia. This is an open-label single site trial designed to expand our safety database and capture additional efficacy (final clinical...
Detailed Description
Subjects will have an in-clinic follow-up on Days 28 +/- 2 days, 42 +/- 4 days and 98 +/- 8 days to assess safety and cure rates. Safety variables including adverse events (AEs) and serious adverse ev...
Eligibility Criteria
Inclusion
- At least 18 years of age
- Subject has a diagnosis of CL in at least one lesion by at least one of the following methods: 1) microscopic identification of amastigotes in stained lesion tissue, or 2) positive culture for promastigotes.
- Subject has a parasitologically confirmed lesion that satisfies the following criteria for an Index lesion:
- ulcerative in character
- lesion size ≥ 1 cm and ≤5 cm (including the area of induration surrounding the lesion)
- not located on the ear, or on a location that in the opinion of the PI is difficult to maintain application of study drug topically.
- Subject has \< 7 leishmaniasis total lesions.
- Subject is willing to forego other forms of treatments for CL including other investigational treatments during the study.
- In the opinion of the investigator, the subject (or their legal guardian) is capable of understanding and complying with the protocol.
Exclusion
- Female with a positive serum pregnancy test or who is breast feeding.
- History of clinically significant medical problems in the investigator's judgment that might interact, either negatively or positively, with topical treatment of leishmaniasis including any immunocompromising condition.
- Age adjusted blood creatinine or blood urea nitrogen (BUN) levels indicative of clinically significant renal disease or aspartate amino transferase (AST), alanine amino transferase (ALT), or total bilirubin that suggest clinically significant hepatic impairment as judged by the PI or subinvestigator. Note: This study is designed to evaluate populations who may have some renal or hepatic dysfunction as the drug has not been shown to have serum levels that would be expected to show renal or hepatic toxicity and treatment of the general population presenting with CL is highly desired based on its safety profile compared to other leishmanial drugs.
- Evidence of disseminated leishmaniasis.
- Received treatment for leishmaniasis with antimonials or any medication likely, in the opinion of the PI, to modify the course of the Leishmania infection within 56 days of starting study treatments.
- History of known or suspected hypersensitivity or idiosyncratic reactions to aminoglycosides.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01494350
Start Date
December 1 2011
End Date
June 1 2012
Last Update
December 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Clinic-Sidi Bouzid
Tunis, Tunisia